Table 3.
Assessment of Cygb, Ngb and CA IX expression in tissue microarrays of human glioblastoma multiforme tumors
| Pathology | Grade | Ngb | Cygb | CA IX |
|---|---|---|---|---|
| Glioblastoma | IV | 3 | 1 | 1 |
| Glioblastoma | IV | 3 | 1 | 1 |
| Pleomorphic glioblastoma | IV | 5 | 4 | 1 |
| Pleomorphic glioblastoma | IV | 5 | 4 | 1 |
| Glioblastoma | IV | 3 | 1 | 2 |
| Glioblastoma | IV | 2 | 1 | 1 |
| Pleomorphic glioblastoma | IV | 5 | 2 | 2 |
| Pleomorphic glioblastoma | IV | 5 | 2 | 2 |
| Glioblastoma | IV | 2 | 2 | 1 |
| Glioblastoma | IV | 2 | 2 | 1 |
| Glioblastoma (sparse) | IV | 2 | 2 | 0 |
| Glioblastoma (necrotic tissue) | IV | 4 | 5 | 1 |
| Glioblastoma (necrotic tissue) | IV | 4 | 5 | 1 |
| Pleomorphic glioblastoma | IV | 4 | 3 | 0 |
| Pleomorphic glioblastoma | IV | 4 | 3 | 0 |
| Glioblastoma | III | 2 | 2 | 0 |
| Glioblastoma | III | 2 | 2 | 0 |
| Glioblastoma | IV | 2 | 3 | 1 |
| Glioblastoma | IV | 3 | 2 | 1 |
| Glioblastoma | IV | 3 | 2 | 1 |
| Glioblastoma | III | 5 | 4 | 0 |
| Glioblastoma | III | 5 | 4 | 0 |
| Glioblastoma | IV | 5 | 2 | 1 |
| Glioblastoma | IV | 5 | 2 | 2 |
| Glioblastoma | IV | 4 | 2 | 0 |
| Glioblastoma | IV | 5 | 2 | 1 |
| Glioblastoma | IV | 5 | 2 | 3 |
| Glioblastoma | IV | 3 | 2 | 0 |
| Glioblastoma | IV | 3 | 3 | 1 |
| Glioblastoma | IV | 4 | 3 | 0 |
| Glioblastoma | IV | 4 | 2 | 2 |
| Glioblastoma | IV | 4 | 2 | 0 |
| Glioblastoma | IV | 3 | 2 | 0 |
| Glioblastoma | III | 5 | 2 | 0 |
| Glioblastoma | III | 5 | 3 | 1 |
| Glioblastoma | IV | 4 | 2 | 3 |
| Glioblastoma | IV | 4 | 2 | 0 |
| Glioblastoma | IV | 5 | 2 | 0 |
| Pleomorphic glioblastoma | IV | 4 | 2 | 1 |
| Pleomorphic glioblastoma | IV | 4 | 3 | 2 |
| Glioblastoma | III | 4 | 3 | 2 |
| Glioblastoma | III | 4 | 3 | 2 |
| Glioblastoma | III | 4 | 2 | 0 |
| Glioblastoma | III | 4 | 3 | 0 |
| Glioblastoma | IV | 4 | 4 | 0 |
| Glioblastoma | IV | 5 | 3 | 0 |
| Glioblastoma | IV | 4 | 3 | 0 |
| Pleomorphic glioblastoma | IV | 5 | 4 | 1 |
| Pleomorphic glioblastoma | IV | 5 | 4 | 1 |
| Glioblastoma | III | 3 | 2 | 0 |
| Glioblastoma | III | 3 | 2 | 0 |
| Glioblastoma | IV | 4 | 3 | 3 |
| Glioblastoma | IV | 4 | 3 | 3 |
| Glioblastoma | IV | 4 | 4 | 0 |
| Glioblastoma | IV | 3 | 2 | 0 |
| Glioblastoma | IV | 4 | 3 | 0 |
| Glioblastoma | IV | 3 | 4 | 0 |
| Glioblastoma | IV | 3 | 4 | 0 |
| Glioblastoma | IV | 2 | 3 | 0 |
| Glioblastoma | IV | 3 | 2 | 0 |
| Adjacent normal brain | - | 4 | 3 | 0 |
| Adjacent normal brain | - | 3 | 2 | 1 |
| Adjacent normal brain | - | 3 | 4 | 0 |
Tissue microarrays constructed from cores obtained from various human glioblastoma miltiforme tumors and normal adjacent brain were purchased from IMGENEX Corporation (San Diego, CA). Immunopositive staining for Ngb, Cygb and CA IX was assessed by two observers who noted the overall tissue staining and the presence of positively stained focal regions. Each section was assigned an overall score, where 0 = absence of positively stained cells; 1 = a few positive cells/regions ( < 10%); 2 = weak positive staining, occasional positive foci; 3 = intermediate staining, occasional positive foci ( < 50%); 4 = strongly positive in most of the section, several positive foci; and 5 = strongly positive throughout with many intensely positive foci. NE = not evaluable.